文献速递胸部肿瘤支持与姑息治疗

调和免疫治疗与放疗联合的随机数据差异:并非所有放疗都等同

Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal.
PubMed 文献 · Eur J Cancer · 2024-02-28

本文针对免疫检查点阻断(ICB)联合放疗(RT)随机数据结果不一致的问题,从RT的双重作用(局部减瘤与全身免疫刺激)及RT方案异质性(剂量、照射部位数、治疗时机、肿瘤生物学等)角度解释差异来源,并据此提出未来临床试验设计应统一RT范式以明确联合治疗价值。

要点

  • RT具有局部减瘤和全身免疫刺激双重作用,应与免疫治疗互补而非简单叠加。
  • RT并非单一药物,其剂量方案、照射部位数、治疗时机等因素均可影响联合疗效。
  • 随机数据差异可能源于异质性人群与临床设置下RT范式不统一,需设计更均一的试验。

核心结论

  • RT与ICB联合的随机数据存在不一致,部分显示改善结局而另一些未显示。
  • RT的双重贡献及RT方案的多维异质性可解释不同随机试验结果的差异。
  • 在采用能为全身治疗带来明确附加价值的特定RT范式、设计更均一条件的试验之前,差异可能持续存在。

研究设计与样本

  • 本文为针对免疫治疗与放疗联合随机数据差异的论述性分析,未报告系统检索范围或样本量。

主要发现

  • RT具有细胞减灭(局部)效应和免疫刺激(全身)效应两种不同贡献。
  • RT应通过针对免疫治疗耐药克隆来补充免疫治疗,免疫治疗应通过针对RT耐药或野外克隆来补充RT。
  • RT不是单一药物,而是可根据剂量方案、既往全身治疗方案、照射部位数、治疗意图/位置/时机、肿瘤生物学和个体免疫状态变化的一组不同药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It remains highly unclear and debatable whether combining radiotherapy (RT) and immune checkpoint blocker (ICB) therapy yields improved outcomes compared to either modality alone. Whereas some randomized data have shown improved outcomes, others have not. As a result of these conflicting data, it is essential to reconcile differences in the data and postulate reasons thereof. This work seeks to address these discrepancies, and uses the lessons learned from both positive and negative trials, including the most cutting-edge data available, in order to guide future clinical trial design and clarify the ideal/expected role of combinatorial therapy going forward. Because RT offers two distinct contributions (cytoreductive (local) effects & immune-stimulating (systemic) effects), RT should complement immunotherapy by addressing immunotherapy-resistant clones, and immunotherapy should complement RT by addressing RT-resistant or out-of-field clones. RT is not merely a single "drug", but rather a constellation of diverse "drugs" that can be varied based on dose regimens, previous systemic therapy regimens, number of irradiated sites, treatment intent/location/timing, tumor biology, and individual patient immunological circumstances. These factors are discussed as an important explanation for the discrepancies in results of various randomized trials in heterogeneous populations and clinical settings, and these discrepancies may continue until trials of more uniform circumstances are designed to use particular RT paradigms that meaningfully add value to systemic therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chang JY, Verma V, Weichselbaum RR, et al. Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal. Eur J Cancer. 2024. PMID: 38430868. doi:10.1016/j.ejca.2024.113972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。